Literature DB >> 19851161

Enriched enrollment randomized withdrawal trial designs of analgesics: focus on methodology.

Nathaniel Katz1.   

Abstract

OBJECTIVES: To systematically identify and critically assess clinical trials that use enriched enrollment randomized withdrawal (EERW) trial design as a methodology for assessing the effect of analgesics pain.
METHODS: A comprehensive literature search was conducted through April 2007 in Medline and Embase to identify all randomized controlled trials that use EERW trial designs. Data were collected from relevant trials and tabulated. Results were categorized on the basis of study designs, preenrichment and postenrichment disposition, discontinuation rates, primary and secondary efficacy results, and respective P values.
RESULTS: The literature search identified 2875 unique citations, most of which were deemed inappropriate for this analysis. The primary reasons for exclusion included inappropriate study design, no available abstract, not a clinical study, and therapeutic area not related to chronic pain. Eight EERW clinical trials of analgesics were identified. Half of the trials were in chronic low back pain, and 5 of 8 trials used an opioid as the active drug. Of the 8 trials, 5 used a parallel design and 3 used crossover designs. The primary efficacy parameter used was pain scores or time to discontinuation, and statistically and clinically significant effects in active treatments relative to placebo were observed after randomization in all trials. The median magnitude of effect was 1.7 on a 10-point scale. Time to exit was a more statistically powerful endpoint than mean pain intensity. DISCUSSIONS: EERW trials are an emerging type of study design that in certain settings may offer advantages over traditional trial designs in characterizing the effects of analgesic medications.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19851161     DOI: 10.1097/AJP.0b013e3181b12dec

Source DB:  PubMed          Journal:  Clin J Pain        ISSN: 0749-8047            Impact factor:   3.442


  20 in total

Review 1.  Comparison of effect sizes between enriched and nonenriched trials of analgesics for chronic musculoskeletal pain: a systematic review.

Authors:  Tie P Yamato; Chris G Maher; Bruno T Saragiotto; Christina Abdel Shaheed; Anne M Moseley; Chung-Wei Christine Lin; Bart Koes; Andrew J McLachlan
Journal:  Br J Clin Pharmacol       Date:  2017-08-11       Impact factor: 4.335

2.  Botulinum toxin type a injections for cervical and shoulder girdle myofascial pain using an enriched protocol design.

Authors:  Andrea L Nicol; Irene I Wu; F Michael Ferrante
Journal:  Anesth Analg       Date:  2014-06       Impact factor: 5.108

Review 3.  Essential statistical principles of clinical trials of pain treatments.

Authors:  Robert H Dworkin; Scott R Evans; Omar Mbowe; Michael P McDermott
Journal:  Pain Rep       Date:  2020-12-18

Review 4.  Design and conduct of confirmatory chronic pain clinical trials.

Authors:  Nathaniel Katz
Journal:  Pain Rep       Date:  2020-12-18

Review 5.  Recommendations for the pharmacological management of neuropathic pain: an overview and literature update.

Authors:  Robert H Dworkin; Alec B O'Connor; Joseph Audette; Ralf Baron; Geoffrey K Gourlay; Maija L Haanpää; Joel L Kent; Elliot J Krane; Alyssa A Lebel; Robert M Levy; Sean C Mackey; John Mayer; Christine Miaskowski; Srinivasa N Raja; Andrew S C Rice; Kenneth E Schmader; Brett Stacey; Steven Stanos; Rolf-Detlef Treede; Dennis C Turk; Gary A Walco; Christopher D Wells
Journal:  Mayo Clin Proc       Date:  2010-03       Impact factor: 7.616

6.  Criterion Validation Testing of Clinical Metrology Instruments for Measuring Degenerative Joint Disease Associated Mobility Impairment in Cats.

Authors:  Margaret E Gruen; Emily H Griffith; Andrea E Thomson; Wendy Simpson; B Duncan X Lascelles
Journal:  PLoS One       Date:  2015-07-10       Impact factor: 3.240

7.  Continuing efficacy of milnacipran following long-term treatment in fibromyalgia: a randomized trial.

Authors:  Daniel J Clauw; Philip J Mease; Robert H Palmer; Joel M Trugman; Yong Wang
Journal:  Arthritis Res Ther       Date:  2013-08-16       Impact factor: 5.156

8.  Patient-reported health-related quality of life, work productivity, and activity impairment during treatment with ALO-02 (extended-release oxycodone and sequestered naltrexone) for moderate-to-severe chronic low back pain.

Authors:  Arnold J Weil; Elizabeth T Masters; Alexandra I Barsdorf; Almasa Bass; Glenn Pixton; Jacquelyn G Wilson; Gernot Wolfram
Journal:  Health Qual Life Outcomes       Date:  2017-10-17       Impact factor: 3.186

9.  Tolerability, Safety, and Effectiveness of Oxycodone DETERx in Elderly Patients ≥65 Years of Age with Chronic Low Back Pain: A Randomized Controlled Trial.

Authors:  Ernest A Kopecky; Ben Vaughn; Scott Lagasse; Melinda O'Connor
Journal:  Drugs Aging       Date:  2017-08       Impact factor: 3.923

10.  Efficacy of opioids versus placebo in chronic pain: a systematic review and meta-analysis of enriched enrollment randomized withdrawal trials.

Authors:  Diana S Meske; Oluwadolapo D Lawal; Harrison Elder; Valerie Langberg; Florence Paillard; Nathaniel Katz
Journal:  J Pain Res       Date:  2018-05-03       Impact factor: 3.133

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.